History of abnormally frequent and/or persistent Qualifying Criteria bacterial infections associated with a demonstrated failure to mount a IgG Specific Antibody deficiency ‘normal’ antibody response to pneumococcal polysaccharides or protein antigens, such as To access IVIg for a period of 12 months, the Evidence items will request the severity tetanus toxoid, after vaccine challenge in a and number of recurrent bacterial following qualifying criteria must be met: patient with a normal serum total IgG infections in the last 12 months and record the type of vaccine challenge concentration. A clinical immunologist must be (Unconjugated pneumococcal consulted to confirm the diagnosis; polysaccharides, Conjugated History of abnormally frequent and/or pneumococcal polysaccharides, Tetanus persistent and significant bacterial infections AND toxoid or Conjugated Hib despite oral antibiotic prophylaxis therapy polysaccharides) and Specific IgG response and details of prophylactic Frequent bacterial infections despite AND antibiotics given. (A) oral antibiotic therapy consistent with best practice recommendations; Documented failure of trial antibody response The purpose of the position statement is to require that the diagnosis of conjugated or unconjugated pneumococcal AND bronchiectasis or suppurative lung vaccine or protein vaccine challenge. disease has been confirmed. (A) Documented failure of serum Please note: a diagnosis of bronchiectasis and/or antibody response to unconjugated suppurative lung disease must be consistent with pneumococcal or protein vaccine position statement of the Thoracic Society of Australia and New Zealand and the Australian challenge. Lung Foundation (Chang et al 2010).
Qualifying Criteria Specific Antibody deficiency To access IVIg for a period of 12 months, the following qualifying criteria must be met: A clinical immunologist must be consulted to confirm the diagnosis; AND Frequent bacterial infections despite oral antibiotic therapy consistent with best practice recommendations; AND Documented failure of serum antibody response to unconjugated pneumococcal or protein vaccine challenge. History of abnormally frequent and/or persistent bacterial infections associated with a demonstrated failure to mount a ‘normal’ IgG antibody response to pneumococcal polysaccharides or protein antigens, such as tetanus toxoid, after vaccine challenge in a patient with a normal serum total IgG concentration. History of abnormally frequent and/or persistent and significant bacterial infections despite oral antibiotic prophylaxis therapy AND Documented failure of antibody response conjugated or unconjugated pneumococcal vaccine or protein vaccine challenge. Please note: a diagnosis of bronchiectasis and/or suppurative lung disease must be consistent with position statement of the Thoracic Society of Australia and New Zealand and the Australian Lung Foundation (Chang et al 2010). Evidence items will request the severity and number of recurrent bacterial infections in the last 12 months and record the type of vaccine challenge (Unconjugated pneumococcal polysaccharides, Conjugated pneumococcal polysaccharides, Tetanus toxoid or Conjugated Hib polysaccharides) and Specific IgG response and details of prophylactic antibiotics given. (A) The purpose of the position statement is to require that the diagnosis of bronchiectasis or suppurative lung disease has been confirmed. (A) trial